Scott D. Locke, a partner at Dorf & Nelson, writes: Fortuitously for inventors and investors in the life sciences industry, five years after 'KSR v. Teleflex,' the Federal Circuit continues to refuse to raise the bar for non-obviousness for new chemical compounds. However, in a recent decision, the court opened the door for a new means by which to challenge these types of claims.
Font Size: 
Determining Non-Obviousness in Patenting of Chemical Compounds
New York Law Journal
June 4, 2012
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.
